New York, Feb 8, 2026, 16:40 (ET) — Closing bell has rung.
- Amgen ended Friday up 4.49% at $384.32, hitting a 52-week high earlier in the session.
- That shift happened as Wall Street rallied, sending the Dow climbing past 50,000.
- Next week brings U.S. jobs and inflation data into focus for traders, along with Amgen’s Feb. 13 dividend record date.
Amgen Inc (AMGN.O) closed out Friday gaining 4.49% to finish at $384.32, after touching $385.12, the highest point in its 52-week range. Roughly 3.84 million shares changed hands.
U.S. markets stayed quiet on Sunday, leaving traders to watch how things play out Monday ahead of a packed slate of postponed data. The U.S. Bureau of Labor Statistics confirmed the January employment figures, delayed, will drop Wednesday. The January CPI now lands on Friday.
The BLS has the next CPI release pegged for Feb. 13 at 8:30 a.m. ET — a move that traders and bond watchers track closely, since the inflation gauge tends to shake up both yields and rate expectations.
The Dow smashed through the 50,000 mark for the first time on Friday, up 2.47% at 50,115.67. The S&P 500 wasn’t far behind, tacking on 1.97%, and the Nasdaq rose 2.18%. Investors snapped their attention back to artificial-intelligence infrastructure and the hefty spending plans fueling the rally.
Amgen shares have surged in the wake of a robust quarterly report earlier this week: revenue climbed 9% to $9.9 billion, while adjusted earnings hit $5.29 per share—both beating Wall Street expectations. Looking out to 2026, the company projects adjusted profit in a $21.60 to $23.00 per share range, with revenue expected between $37 billion and $38.4 billion. On the earnings call, commercial chief Murdo Gordon commented, “There is dissatisfaction with the weekly GLP-1s,” and described Amgen’s MariTide obesity candidate as “a paradigm-changing opportunity.” Over at Citi, analyst Geoffrey Meacham remarked the guidance “suggests modest upside.” Reuters
Amgen put out its earnings release and non-GAAP reconciliation in an 8-K, according to a Feb. 3 SEC filing, listing them under “Results of Operations and Financial Condition.” SEC
Income investors, take note: Amgen’s board has approved a first-quarter dividend of $2.52 per share for 2026. The payout is set for March 6, going to shareholders who are on the books as of Feb. 13.
Still, the surge brings back a classic headache for major pharma players: older blockbusters facing price squeezes. CVS Health’s Caremark unit plans to kick Amgen’s Prolia off some of its preferred drug lists beginning April 1, swapping in cheaper biosimilars—almost identical to original biologics—following the expiration of key U.S. patents in 2025. Prolia pulled in around $4.4 billion in worldwide sales that year, according to Amgen.
Payer pressure like this matters—a lot. It can trigger faster moves off branded drugs and slam revenues harder and sooner than most investors bake in. The risk if things break bad? Sharper price drops, biosimilars catching on quicker, and whatever good shows up in the top-line numbers gets drowned out.
The obesity trade remains the sentiment lever. Right now, Novo Nordisk and Eli Lilly are running the show—investors react fast, pushing rivals in or out on every scrap of trial data or hint about supply.
Amgen’s big move has traders wondering: was this just a sharp squeeze in a bullish market, or is the stock building something more solid above the mid-$300s? Monday will tell the story—buyers need to show up without the boost from Friday’s rebound.
Then comes a run of market-moving events: the postponed U.S. jobs numbers land Feb. 11, with CPI data due on Feb. 13. Amgen’s Feb. 13 dividend record date falls between the two.
